Key Points
- Director Andrew Schwab sold 114,700 shares of CAMP4 Therapeutics at an average price of $4.54, generating $520,738 and reducing his holdings by 4.45% to 2,465,298 shares.
- CAMP opened at $4.48 and was up 0.4%, with a market capitalization of about $281 million. The company reported a quarterly loss of $0.58 per share, missing estimates by $0.34, on revenue of $1.78 million.
- Analyst sentiment remains generally positive: seven analysts rate the stock a Buy, one a Hold and one a Sell, producing a “Moderate Buy” consensus and an average price target of $9.56.
CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) Director Andrew Schwab sold 32,018 shares of the company's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $4.50, for a total transaction of $144,081.00. Following the completion of the transaction, the director owned 2,433,280 shares in the company, valued at approximately $10,949,760. This trade represents a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
CAMP4 Therapeutics Price Performance
Shares of CAMP opened at $4.48 on Friday. CAMP4 Therapeutics Corporation has a 1-year low of $1.41 and a 1-year high of $7.75. The company has a market capitalization of $281.12 million, a P/E ratio of -1.93 and a beta of 0.22. The firm's 50 day simple moving average is $4.12 and its 200 day simple moving average is $4.34.
CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.34). The company had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. On average, equities analysts anticipate that CAMP4 Therapeutics Corporation will post -0.59 earnings per share for the current year.
Institutional Investors Weigh In On CAMP4 Therapeutics
A number of hedge funds have recently made changes to their positions in CAMP. Bank of America Corp DE purchased a new stake in shares of CAMP4 Therapeutics in the 2nd quarter valued at $78,000. Trails Edge Capital Partners LP purchased a new position in CAMP4 Therapeutics in the 2nd quarter worth $8,446,935,000. Jupiter Topco LLC purchased a new position in CAMP4 Therapeutics in the 2nd quarter worth $27,581,000. 5AM Venture Management LLC bought a new stake in CAMP4 Therapeutics in the second quarter worth $25,647,928,000. Finally, BlackRock Inc. bought a new stake in CAMP4 Therapeutics in the second quarter worth $7,185,000.
Analyst Ratings Changes
CAMP has been the subject of several research reports. JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a "neutral" rating to an "overweight" rating and upped their target price for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. UBS Group set a $15.00 price target on CAMP4 Therapeutics in a research report on Friday, August 14th. Zacks Research raised CAMP4 Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday, August 17th. Piper Sandler reiterated an "overweight" rating and issued a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Finally, Weiss Ratings upgraded CAMP4 Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, August 14th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.56.
Get Our Latest Analysis on CAMP
CAMP4 Therapeutics Company Profile
(
Get Free Report)
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
